Patient P-02409

Synthetic patientMETA-24 · Day 115 · 35–44 · M · baseline S01Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

62%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S01
Day 26 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 74 SC-12 recommended — Supportive Compound SC-12
Day 75 GI-04 recommended — GI Support Protocol GI-04
Day 75 Patient accepted — Started SC-12 in the companion
Day 76 Patient accepted — Started GI-04 in the companion
Day 81 No meaningful change — Supportive Compound SC-12
Day 84 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 26.

Primary contributors, last 14 days

Treatment adherence-10
GI instability-4
Toxicity-4
Inflammatory activity-3
Nutritional resilience+3

What helped?

Supportive Compound SC-12Day 74
Result: no meaningful change
GI Support Protocol GI-04Day 75
Result: no meaningful change

LIFE OS recommendation

Monitoring Escalation ME-01

79%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 65
- WearableHRV 20 ms, trending down
Autonomic recovery ↑65
- WearableResting HR 88 bpm
- Wearable3,289 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
Drug metabolism and exposure ↑20
- BloodToxicity index 55

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3 · butyrate capacity 44/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 17 ms
Sleep: 6.7 h
Steps: 3,354
Resting HR: 87 bpm

Daily log: GI score 59, nutritional resilience 39, adherence 55.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02508	48%	S14	ME-01	improved	51
P-02165	46%	S14	ME-01	improved	59
P-02381	42%	S14	SC-12	improved	52
P-02236	41%	S14	GI-04	improved	45
P-02151	39%	S04	CR-01	improved	49
P-02132	38%	S14	SC-12	improved	40
P-02244	38%	S14	GI-04	improved	46
P-02693	38%	S14	ME-01	improved	41
P-02268	37%	S14	GI-04	improved	43
P-02666	37%	S14	ME-01	improved	51
P-02209	36%	S12	GI-04	improved	36
P-02018	35%	S01	GI-04	improved	46